U.S. markets closed
  • S&P Futures

    3,849.50
    +1.25 (+0.03%)
     
  • Dow Futures

    31,021.00
    +8.00 (+0.03%)
     
  • Nasdaq Futures

    11,891.50
    +11.25 (+0.09%)
     
  • Russell 2000 Futures

    1,730.00
    +1.40 (+0.08%)
     
  • Crude Oil

    98.31
    -0.22 (-0.22%)
     
  • Gold

    1,740.00
    +3.50 (+0.20%)
     
  • Silver

    19.18
    +0.02 (+0.11%)
     
  • EUR/USD

    1.0190
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    2.9130
    +0.1040 (+3.70%)
     
  • Vix

    26.73
    -0.81 (-2.94%)
     
  • GBP/USD

    1.1927
    +0.0005 (+0.05%)
     
  • USD/JPY

    135.7900
    -0.1250 (-0.09%)
     
  • BTC-USD

    20,534.24
    +241.17 (+1.19%)
     
  • CMC Crypto 200

    446.89
    +11.37 (+2.61%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,259.63
    +151.98 (+0.58%)
     

Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29, 2021 through December 2, 2021.

About Larimar Therapeutics

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in the U.S. as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715